Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
02 Agosto 2023 - 2:00PM
Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company
dedicated to advancing health equity and outcomes through the
delivery of accurate infectious disease testing in the moment of
need, at the point of care (POC), today announced that it has
appointed Dr. Andrew A. Lukowiak as president and chief scientific
officer, effective August 1, 2023.
Dr. Lukowiak has more than 20 years of senior leadership
experience in the clinical diagnostics industry at both publicly
traded and privately held commercial-stage companies. As a member
of the executive leadership team, he will be responsible for
leading the assay development, platform engineering, operations,
regulatory and clinical affairs functions for Talis Biomedical.
“We are thrilled to welcome Andrew to our leadership team as we
continue to develop the Talis One® test menu and plan to initiate
clinical studies to support our pursuit of multiple 510(k)
clearances,” said Rob Kelley,” chief executive officer at Talis
Biomedical. “Andrew’s executive experience and proven ability to
bring clinical diagnostics to market, from concept to
commercialization, will enhance the strong teams we have built
during this pivotal period of execution to deliver a menu of
women’s and sexual health tests at the point of care.”
Dr. Lukowiak joins Talis Biomedical from Epigenomics AG where he
served as president and chief scientific officer and developed the
next generation of its blood-based colorectal cancer screening
test. Prior to this, he was the chief executive officer at
Millenium Health, a leading national toxicology laboratory
specializing in clinical testing to support physicians in their
treatment of substance use disorder. He has also held senior
leadership roles at a variety of molecular diagnostics companies
including Althea Dx, Genmark Dx, Hologic and Third Wave
Technologies. Throughout his career, Dr. Lukowiak has been
responsible for the development of numerous in vitro diagnostic and
laboratory developed tests in oncology, pharmacogenetics, inherited
diseases and women’s health. Dr. Lukowiak holds a Bachelor of
Science in Biology from Pennsylvania State University and a Ph.D.
in Genetics from the University of Georgia.
“By having made such a significant upfront investment in
building a cost-effective, uniquely differentiated platform, I
believe Talis Bio is well positioned in the POC space with strong
potential to decentralize the women’s and sexual health markets,”
said Dr. Lukowiak. “I am excited to work with such a
high-performing group of professionals and look forward to building
out the Talis One test menu alongside the entire team.”
In connection with his appointment, the Company’s Board of
Directors has granted an incentive stock option to Dr. Lukowiak
pursuant to the Company’s 2021 Equity Incentive Plan to purchase up
to 13,477 shares of the Company’s common stock at an exercise price
of $7.42 per share (the “Incentive Stock Option”). As an inducement
award to Dr. Lukowiak, the Company’s Board of Directors also
has granted a nonqualified stock option to Dr. Lukowiak pursuant to
the Company’s 2021 Inducement Plan to purchase up to 17,098 shares
of the Company’s common stock at an exercise price of $7.42 per
share as an inducement material to Dr. Lukowiak entering into
employment with the Company in accordance with Nasdaq Listing Rule
5635(c)(4). All of the stock option awards granted to Dr. Lukowiak
will be subject to vesting over four years, with 25% of the shares
vesting on the one year anniversary of Dr. Lukowiak’s start date,
and the remainder vesting monthly over the following thirty-six
(36) months, subject to his continued employment and the terms and
conditions of the stock option agreement.
About Talis BiomedicalTalis Biomedical is
dedicated to advancing health equity and outcomes through the
delivery of accurate infectious disease testing in the moment of
need, at the point of care. The Company plans to develop and
commercialize innovative products on its sample-to-answer Talis
One® system to enable accurate, low cost, and rapid molecular
testing. For more information, visit talisbio.com.
Forward-Looking Statements This press release
may contain forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Words such as
“may,” “might,” “will,” “would,” “should,” “believe,” “expect,”
“anticipate,” “could,” “estimate,” “continue,” “predict,”
“potential,” “forecast,” “project,” “plan,” “intend” or similar
expressions, or other words that convey uncertainty of future
events or outcomes can be used to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the differentiation of
our Talis One platform, the size and potential market opportunity
for our products, and our ability to develop a test menu. These
statements are not guarantees of future performance and are subject
to certain risks, uncertainties and other factors that could cause
actual results and events to differ materially and adversely from
those indicated by such forward-looking statements including, among
others, the Company’s ability to attain regulatory approval for our
products, launch and gain market acceptance for our products and to
accurately forecast and meet customer demand, and attract and
maintain our key employees and other risks and uncertainties that
are described more fully in the “Risk Factors” section and
elsewhere in our filings with the Securities and Exchange
Commission and available at www.sec.gov, including in our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q. These
statements are based upon information available to us as of the
date of this press release, and while we believe such information
forms a reasonable basis for such statements, such information may
be limited or incomplete, and our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. These
statements are inherently uncertain and investors are cautioned not
to unduly rely upon these statements. Any forward-looking
statements that we make in this announcement speak only as of the
date of this press release, and Talis Biomedical assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise after the date of
this press release, except as required under applicable law.
Contact Media & InvestorsEmily
Faucetteefaucette@talisbio.com415-595-9407
Grafico Azioni Talis Biomedical (NASDAQ:TLIS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Talis Biomedical (NASDAQ:TLIS)
Storico
Da Set 2023 a Set 2024